11.88
-0.27 (-2.22%)
| Previous Close | 12.15 |
| Open | 11.87 |
| Volume | 1,353,681 |
| Avg. Volume (3M) | 786,191 |
| Market Cap | 922,024,704 |
| Price / Sales | 16.38 |
| Price / Book | 1.97 |
| 52 Weeks Range | |
| Earnings Date | 8 Apr 2025 - 14 Apr 2025 |
| Operating Margin (TTM) | -340.67% |
| Diluted EPS (TTM) | -2.79 |
| Quarterly Revenue Growth (YOY) | 11.30% |
| Total Debt/Equity (MRQ) | 5.54% |
| Current Ratio (MRQ) | 6.26 |
| Operating Cash Flow (TTM) | -191.72 M |
| Levered Free Cash Flow (TTM) | -106.56 M |
| Return on Assets (TTM) | -31.08% |
| Return on Equity (TTM) | -64.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Nurix Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 2.50 |
|
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.41% |
| % Held by Institutions | 111.85% |
| 52 Weeks Range | ||
| Median | 27.00 (127.27%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 29 Apr 2025 | 27.00 (127.27%) | Buy | 11.44 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |